GSK plc announced it has started shipping doses of its trivalent influenza vaccines to U.S. healthcare providers and pharmacies in preparation for the 2024-25 flu season. This immediately follows a licensing and lot-release approval from the US Food and Drug Administration, the company noted. “In partnership with regulatory bodies, GSK worked quickly to ensure production, approval and availability of trivalent influenza vaccines with the recommended composition for the 2024-25 flu season. GSK expects to distribute over 36 million doses of its trivalent influenza vaccines in the US this season. Both FLULAVAL and FLUARIX will be available in a 0.5mL, single-dose, pre-filled syringe and are indicated for people six months of age and older,” GSK stated.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on GSK:
- GSK Pharma put volume heavy and directionally bearish
- iTeos Therapeutics announces first patient dosed in GALAXIES Lung-301 study
- GSK downgraded to Neutral from Buy at UBS
- FDA to evaluate potential risk of neural tube birth defects with dolutegravir
- GSK Acquires Key Vaccine Rights from Partner CureVac in €1.45B Deal